{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:17:27Z","timestamp":1769044647982,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen GmbH, Germany"},{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The PERI-DYS study aims to characterize two groups of patients with dyslipidaemia at very high CV risk: PCSK9i receivers and patients qualifying for but not receiving PCSK9i.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an observational study by office-based and clinic-based physicians, mainly cardiologists and other internists in Germany, with data extracted from patient charts. ClinicalTrials.gov identifier NCT03110432.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1659 patients were enrolled across 70 sites. The majority of patients (91.0%) were reported as having mixed dyslipidaemia or non-familial or heterozygous familial hypercholesterolemia. At enrolment, 794 (47.9%) of patients were PCSK9i receivers (of these 65.9% ongoing, and 34.1% newly treated within 30\u00a0days before their baseline visit). Among PCSK9i receivers, the majority had evolocumab 140\u00a0mg (<jats:italic>n<\/jats:italic>\u2009=\u2009632, 38.1% of total). PCSK9i receivers compared to non-receivers were about 2\u00a0years younger and had a lower proportion of males. In terms of comorbidities, they had (statistically significantly) more often CAD, and less often PAD, diabetes mellitus, arterial hypertension and chronic renal disease. The calculated untreated median LDL-C was 187\u00a0mg\/dl (IQR 127; 270) in ongoing PCSK9i receivers, 212\u00a0mg\/dl (IQR 132; 277) in newly treated PCSK9i receivers, and 179\u00a0mg\/dl (IQR 129; 257) in non-receivers. Physician-reported statin intolerance was much more common in the two PCSK9i receiver groups as compared to non-receivers (67.3% versus 15.3%). Consequently, patients in the PCSK9i groups received fewer concomitant statins. Mean total cholesterol (143 vs. 172\u00a0mg\/dl) and LDL-C (69 vs. 99\u00a0mg\/dl) were considerably lower in ongoing PCSK9i receivers compared to non-receivers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PCSK9i receivers are characterized by higher baseline LDL-C and a higher portion of statin intolerance compared to those qualified for but not-receiving PCSK9i treatment. On-treatment, LDL-C was lower in PCSK9i receivers. Ongoing follow-up will determine the prognostic importance of these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-022-07386-0","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T09:11:42Z","timestamp":1664529102000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Ulrich","family":"Laufs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fraass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Dexl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunnhild","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker J. J.","family":"Schettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Collaborators in the PERI-DYS Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"No\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz-Rudolf","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anselm","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Taggeselle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwittay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Janseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Axthelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Spens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayham","family":"Al-Zoebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker J.J.","family":"Schettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toralf","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Eberhand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Borucki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Knittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Cathrin","family":"Koschker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Holger","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Tekiyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Spitth\u00f6ver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Beigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sinning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Jahnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Gysan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Ruef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Wei\u00dfbrodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Killat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Beckermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Gerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Salbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Raddatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Ries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markolf","family":"Hanefeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilka","family":"Simon-Wager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Zugck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Twisselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Brode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansj\u00f6rg","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Oettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Ke\u00dfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Meesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Stach-Jablonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"9841","key":"7386_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"CTT Collaborators","year":"2012","unstructured":"Collaborators CTT. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"14","key":"7386_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769\u2013818.","journal-title":"Eur Heart J"},{"key":"7386_CR3","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, BaireyMerz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934 (25 Pt B).","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"7386_CR4","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"1","key":"7386_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"6","key":"7386_CR6","first-page":"641","volume":"22","author":"M McDonagh","year":"2016","unstructured":"McDonagh M, Peterson K, Holzhammer B, Fazio S. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016;22(6):641\u201353.","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"7386_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"M Sabatine","year":"2017","unstructured":"Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. NEJM. 2017;376(18):1713\u201322.","journal-title":"NEJM"},{"issue":"16","key":"7386_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"key":"7386_CR9","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage III \u2013 \u00dcbersicht \u00fcber Verordnungseinschr\u00e4nkungen und -ausschl\u00fcsse Evolocumab; February 9th 2016. https:\/\/www.g-ba.de\/downloads\/39-261-2495\/2016-02-09_AM-RL-III_SN_Evolocumab.pdf; Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage III \u2013 \u00dcbersicht \u00fcber Verordnungseinschr\u00e4nkungen und -ausschl\u00fcsse Evolocumab; February 9th 2016. https:\/\/www.g-ba.de\/downloads\/40-268-3595\/2016-02-09_AM-RL-III_SN_Evolocumab_TrG.pdf."},{"key":"7386_CR10","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage III \u2013 \u00dcbersicht \u00fcber Verordnungseinschr\u00e4nkungen und -ausschl\u00fcsse Alirocumab; May 4th 2016. https:\/\/www.g-ba.de\/downloads\/39-261-2575\/2016-04-26_AM-RL-III-SN_Alirocumab.pdf; Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage III \u2013 \u00dcbersicht \u00fcber Verordnungseinschr\u00e4nkungen und -ausschl\u00fcsse Alirocumab; May 4th 2016. https:\/\/www.g-ba.de\/downloads\/40-268-3755\/2016-04-26_AM-RL-III_SN_Alirocumab_TrG.pdf."},{"key":"7386_CR11","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Gemeinsamer Bundesausschuss (G-BA) 2013. Beratungsverfahren \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung (MVV-RL): Dokumentationsvorgaben zur Indikationsstellung der Lp(a)-Apherese. Abschlussbericht. January 17th 2013. Internet: https:\/\/www.g-ba.de\/downloads\/40-268-2183\/2013-01-17_MVV-RL-DokIndApherese_ZD.pdf."},{"issue":"2","key":"7386_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40256-017-0246-z","volume":"18","author":"PB Rane","year":"2018","unstructured":"Rane PB, Patel J, Harrison DJ, Shepherd J, Leith A, Bailey H, et al. Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors. Am J Cardiovasc Drugs. 2018;18(2):103\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"40","key":"7386_CR13","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","volume":"41","author":"A Allahyari","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P. Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41(40):3900\u20139.","journal-title":"Eur Heart J"},{"key":"7386_CR14","doi-asserted-by":"publisher","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020 (online first).\u00a0https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"7386_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.atherosclerosis.2018.08.050","volume":"277","author":"N Schmidt","year":"2018","unstructured":"Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, et al. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis. 2018;277:314\u201322.","journal-title":"Atherosclerosis"},{"key":"7386_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.atherosclerosis.2018.08.008","volume":"277","author":"M Vrablik","year":"2018","unstructured":"Vrablik M, Raslov\u00e1 K, Vohnout B, Blaha V, Satny M, Kyselak O, et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis. 2018;277:355\u201361.","journal-title":"Atherosclerosis"},{"issue":"9","key":"7386_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","volume":"105","author":"U Laufs","year":"2016","unstructured":"Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol. 2016;105(9):783\u201390.","journal-title":"Clin Res Cardiol"},{"issue":"7404","key":"7386_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J. 2003;326(7404):1423\u201330.","journal-title":"Brit Med J"},{"issue":"35","key":"7386_CR19","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/eurheartj\/ehaa582","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Isermann B. Statin intolerance: myths and facts. Eur Heart J. 2020;41(35):3343\u20135.","journal-title":"Eur Heart J"},{"key":"7386_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.06.111","volume":"287","author":"E Waldmann","year":"2019","unstructured":"Waldmann E, Altenhofer J, Henze K, Parhofer KG. Pcsk9-inhibition in routine clinical practice: real world data from Germany. Atherosclerosis. 2019;287: e38.","journal-title":"Atherosclerosis"},{"issue":"3","key":"7386_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","volume":"6","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, von Stritzky B, Pietschmann N, Dorn C, Paar WD. PEARL: a non-interventional study of real-world alirocumab use in german clinical practice. Drugs - real world outcomes. 2019;6(3):115\u201323.","journal-title":"Drugs - real world outcomes"},{"issue":"1","key":"7386_CR22","doi-asserted-by":"publisher","first-page":"e001572","DOI":"10.1136\/openhrt-2021-001572","volume":"8","author":"D Steffens","year":"2021","unstructured":"Steffens D, Bramlage P, Muller J, Dorn C, Paar WD, Scheeff C, et al. Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease. Open Heart. 2021;8(1):e001572. https:\/\/doi.org\/10.1136\/openhrt-2021-001572","journal-title":"Open Heart."},{"issue":"4","key":"7386_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacl.2021.04.011","volume":"15","author":"R Alonso","year":"2021","unstructured":"Alonso R, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, de Andres R, Arroyo-Olivares R, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021;15(4):584\u201392.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"7386_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12325-021-01962-w","volume":"39","author":"D Nanchen","year":"2022","unstructured":"Nanchen D, Carballo D, Bilz S, Rickli H, Koskinas KC, Mach F, et al. Effectiveness, adherence, and safety of evolocumab in a Swiss multicenter prospective observational study. Adv Ther. 2022;39(1):504\u201317. https:\/\/doi.org\/10.1007\/s12325-021-01962-w Epub 2021.","journal-title":"Adv Ther."},{"issue":"5","key":"7386_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/clc.23600","volume":"44","author":"NR Desai","year":"2021","unstructured":"Desai NR, Wade RL, Xiang P, Pinto L, Nunna S, Wang X, et al. Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab. Clin Cardiol. 2021;44(5):715\u201322.","journal-title":"Clin Cardiol"},{"issue":"5","key":"7386_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682\u20139.","journal-title":"Am Heart J"},{"issue":"15","key":"7386_CR27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580\u201390.","journal-title":"JAMA"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07386-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T10:32:24Z","timestamp":1708338744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["7386"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07386-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"19 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ulrich Laufs: Leipzig University has received research funding from Amgen, Daiichi Sankyo, Novartis. UL has received honoraria from Amarin, Amgen, Daiichi Sankyo, Novartis, Sanofi, Synlab. Andreas L. Birkenfeld: none reported. Uwe Fraass: full-time employee of Amgen GmbH, Germany. Bernd Hohenstein: none reported. Carsten Siegert: full-time employee of Amgen GmbH, Germany. Jens Klotsche: none reported. Elisabeth Steinhagen-Thiessen: none reported. David Pittrow: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz\/Novartis, Viatris, MSD. Stefan Dexl: full-time employee of Amgen GmbH, Germany. Sunnhild Salmen: full-time employee of Amgen GmbH, Germany. Volker J.J. Schettler: received consultancy fees and\/or speaker\u2019s bureaus and\/or Data Monitoring Committee activity from Amgen GmbH, Daiichi Sankyo GmbH, Novartis GmbH, Sanofi-Aventis GmbH. Klaus G. Parhofer: has received research funding and honoraria for consultancy and\/or speaker\u2019s bureaus and\/or Data Monitoring Committee activity from Akcea, Amarin, Amgen, Boehringer-Ingelheim, Dr. Sch\u00e4r, Daiichi Sankyo, Ionis, MSD, Novartis, Pfizer, Regeneron, Sanofi, and Silence Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}